Product Name: FGFR3 (407-420)
Product Number: PE-01ARW95
Size: 200 µg      Price:48.00
1 mg      $US96.00
5 mg      210.00
Peptide Name: FGFR3 (407-420)

Product Use: Services as a blocking peptide for use with the FGFR3 (FGFR3-2) rabbit polyclonal antibody (Cat. No.: AB-NK228) that is also available from Kinexus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CGSPTVHKISRFPLK

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1669 Da

Peptide Purity Percent after Synthesis and Purification: 95

Peptide Appearance: White powder
Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: FGFR3 pan-specific antibody (Cat. No.: AB-NK228)

Scientific Background: FGFR3 is a protein-tyrosine kinase of the TK group and FGFR family. It serves as the cell-surface receptor for fibroblast growth factor (FGF) ligands, which induces dimerization and autophosphorylation. Phosphorylation of Y724 and Y760 increases phosphotransferase activity and induces interaction with SH2-B-beta. The FGFR3 protein plays a role in the regulation of cell proliferation, differentiation, and apoptosis. FGFR3 plays a role in several important cellular processes, including regulation of cell growth and division, determination of cell fate, formation of blood vessels, wound healing and embryo development. FGFR3 is involved in the development and maintenance of bone and brain tissue. FGFR3 has an essential role in the regulation of chondrocyte differentiation, proliferation, and apoptosis, as well as in the regulation of osteogenesis and osteoblast-mediated postnatal bone mineralization. FGFR3 expression is necessary for normal skeletal development. Activation of FGFR3 stimulates several downstream intracellular signalling cascades, including the MAPK and the Akt signalling pathways. FGFR3 is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Mutations in the FGFR3 gene that result in overactive or constitutive kinase phosphotransferase activity have been associated with several cancer types as they cause aberrant cell proliferation and differentiation as well as reduced apoptosis. Mutations in FGFR3 have been implicated in causing bladder cancer, cancer of white blood cells (multiple myeloma) and cervical cancer. FGFR3 has also been linked with the development of colorectal cancer as well as dwarfism and facial and other morphogenetic disorders.